Isofol´s oncology seminar

Watch the seminar from January 30, 2020 >>


Arfolitixorin - a drug candidate
for treatment of colorectal cancer

Read more

More than 370 000 CRC patients
could be treated
with arfolitixorin

Read more

The global Phase III clinical study - AGENT

The AGENT study with arfolitixorin

is ongoing at more than 70 hospitals

in The US, Canada and Europe

Read More

See how arfolitixorin
works in cancer cells

See the animation



Startpage 2